Learn how Exazym® enables ultra-sensitive detection of clinical biomarkers in immunodiagnostics.
Measurements of low abundance biomolecules, including proteins and nucleic acids, remain a critical challenge in many clinical and diagnostic applications due to insufficient sensitivity. But what if you were able to amplify true signal by 10 to 100 times with no extra equipment and only minor changes to your process? That is exactly what Exazym® does.
In this white paper we share our most recent research which demonstrates how Exazym®, our unique BOLD immunoassay signal amplification method, is capable of achieving levels of sensitivity that exceed those produced by expensive closed systems while maintaining selectivity.
Exazym® works with any standard immunoassay and requires no investment in new equipment. As such, it has the potential to make world-class immunoassay amplification accessible to all researchers. Our hope is that this will accelerate the progress of translational research, health screens, and diagnostics testing across a broad range of therapeutic areas, including oncology, neurology, cardiology, inflammation, and infectious disease.
We invite you to download this white paper to learn more about this game-changing amplification method.
See Exazym® in action
This White Paper is a must-read for anyone involved with health screening, diagnostic testing, or translational research who could benefit from a better signal amplification method.
Download our new White Paper for:
- Our latest results with human anti-spike IgG antibodies in serum samples and spike-antigen assessment (both key biomarkers related to Sars-Cov-2)
- The science behind our patented BOLD signal amplification technology
- Discussion of applications and further developments
Download the White Paper Now
Essential reading for any researcher working with immunoassays in therapeutic areas, such as:
- infectious disease
Download your free copy